Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Post-Pfizer Deal Setback, Ablynx Finds Data Differentiating Its Nanobody Ozoralizumab From Other Anti-TNFs

This article was originally published in The Pink Sheet Daily

Executive Summary

Ablynx releases Phase II open-label extension clinical data showing its lead nanobody, ozoralizumab, allows individualized dosing in rheumatoid arthritis and doesn't induce neutralizing antibodies that affect efficacy, potentially differentiating it from marketed TNF inhibitors.


Related Content

Ablynx: Balancing Partners And Pipeline
Amgen’s Stealth Enbrel Patent May Block Biosimilars; Scenario May Apply To Other Biologics


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts